Allosteric inhibition of the nonMyristoylated c-Abl tyrosine kinase by phosphopeptides derived from Abi1/Hssh3bp1

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1783, Issue 5, 2008, Pages 737-747

  Xiong, Xiaoling ^a   Cui, Ping ^a   Hossain, Sajjad ^a   Xu, Rong ^b   Warner, Brian ^a   Guo, Xinhua ^a   An, Xiuli ^a   Debnath, Asim K ^a   Cowburn, David ^b   Kotula, Leszek ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b NEW YORK STRUCTURAL BIOLOGY CENTER   (United States)

Author keywords

Abi1; Allosteric mechanism; c Abl; Hssh3bp1; SH3 and SH2 domain; Tyrosine kinase activity

Indexed keywords

ABELSON KINASE; PERVANADATE; PHOSPHOPEPTIDE; PROTEIN ABI1; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME REGULATION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ALLOSTERIC REGULATION; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CELL LINE; CYTOSKELETAL PROTEINS; ENZYME INHIBITORS; LIGANDS; MOLECULAR SEQUENCE DATA; PHOSPHOPEPTIDES; PROTO-ONCOGENE PROTEINS C-ABL; SRC HOMOLOGY DOMAINS; TYROSINE; VANADATES;

EID: 41949113371     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2008.01.028     Document Type: Article

References (42)

1. Koleske A.J., Gifford A.M., Scott M.L., Nee M., Bronson R.T., Miczek K.A., and Baltimore D. Essential roles for the Abl and Arg tyrosine kinases in neurulation. Neuron 21 (1998) 1259-1272
2. Woodring P.J., Hunter T., and Wang J.Y. Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases. J. Cell Sci. 116 (2003) 2613-2626
3. Druker B.J., Sawyers C.L., Capdeville R., Ford J.M., Baccarani M., and Goldman J.M. Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program) (2001) 87-112
4. Goldman J.M., and Melo J.V. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N. Engl. J. Med. 349 (2003) 1451-1464
5. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Druker B.J., and Lydon N.B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56 (1996) 100-104
6. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., and Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344 (2001) 1031-1037
7. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., and Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
8. von Bubnoff N., Schneller F., Peschel C., and Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359 (2002) 487-491
9. Druker B.J. Circumventing resistance to kinase-inhibitor therapy. N. Engl. J. Med. 354 (2006) 2594-2596
10. Hantschel O., and Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat. Rev., Mol. Cell Biol. 5 (2004) 33-44
11. Courtneidge S.A. Cancer: Escape from inhibition. Nature 422 (2003) 827-828
12. Wang J.Y. Controlling Abl: auto-inhibition and co-inhibition?. Nat. Cell Biol. 6 (2004) 3-7
13. Williams J.C., Weijland A., Gonfloni S., Thompson A., Courtneidge S.A., Superti-Furga G., and Wierenga R.K. The 2.35 A crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions. J. Mol. Biol. 274 (1997) 757-775
14. Xu W., Doshi A., Lei M., Eck M.J., and Harrison S.C. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol. Cell 3 (1999) 629-638
15. Hantschel O., Nagar B., Guettler S., Kretzschmar J., Dorey K., Kuriyan J., and Superti-Furga G. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112 (2003) 845-857
16. Nagar B., Hantschel O., Young M.A., Scheffzek K., Veach D., Bornmann W., Clarkson B., Superti-Furga G., and Kuriyan J. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112 (2003) 859-871
17. Thomas S.M., and Brugge J.S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 13 (1997) 513-609
18. Nagar B., Hantschel O., Seeliger M., Davies J.M., Weis W.I., Superti-Furga G., and Kuriyan J. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol. Cell 21 (2006) 787-798
19. Adrian F.J., Ding Q., Sim T., Velentza A., Sloan C., Liu Y., Zhang G., Hur W., Ding S., Manley P., Mestan J., Fabbro D., and Gray N.S. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol. 2 (2006) 95-102
20. Cowburn D., Zheng J., Xu Q., and Barany G. Enhanced affinities and specificities of consolidated ligands for the Src homology (SH) 3 and SH2 domains of Abelson protein-tyrosine kinase. J. Biol. Chem. 270 (1995) 26738-26741
21. Dai Z., and Pendergast A.M. Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Genes Dev. 9 (1995) 2569-2582
22. Shi Y., Alin K., and Goff S.P. Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity. Genes Dev. 9 (1995) 2583-2597
23. Macoska J.A., Xu J., Ziemnicka D., Schwab T.S., Rubin M.A., and Kotula L. Loss of expression of human spectrin src homology domain binding protein 1 is associated with 10p loss in human prostatic adenocarcinoma. Neoplasia 3 (2001) 99-104
24. Ziemnicka-Kotula D., Xu J., Gu H., Potempska A., Kim K.S., Jenkins E.C., Trenkner E., and Kotula L. Identification of a candidate human spectrin Src homology 3 domain-binding protein suggests a general mechanism of association of tyrosine kinases with the spectrin-based membrane skeleton. J. Biol. Chem. 273 (1998) 13681-13692
25. Xu J., Ziemnicka D., Merz G.S., and Kotula L. Human spectrin Src homology 3 domain binding protein 1 regulates macropinocytosis in NIH 3T3 cells. J. Cell Sci. 113 Pt 21 (2000) 3805-3814
26. Tanis K.Q., Veach D., Duewel H.S., Bornmann W.G., and Koleske A.J. Two distinct phosphorylation pathways have additive effects on Abl family kinase activation. Mol. Cell. Biol. 23 (2003) 3884-3896
27. Brasher B.B., and Van Etten R.A. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J. Biol. Chem. 275 (2000) 35631-35637
28. Songyang Z., Carraway III K.L., Eck M.J., Harrison S.C., Feldman R.A., Mohammadi M., Schlessinger J., Hubbard S.R., Smith D.P., Eng C., et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373 (1995) 536-539
29. Nedrelow J.H., Cianci C.D., and Morrow J.S. c-Src binds alpha II spectrin's Src homology 3 (SH3) domain and blocks calpain susceptibility by phosphorylating Tyr1176. J. Biol. Chem. 278 (2003) 7735-7741
30. Lehrer S.S. Solute perturbation of protein fluorescence. The quenching of the tryptophyl fluorescence of model compounds and of lysozyme by iodide ion. Biochemistry 10 (1971) 3254-3263
31. Mayer B.J., Jackson P.K., Van Etten R.A., and Baltimore D. Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo. Mol. Cell. Biol. 12 (1992) 609-618
32. Zhao Z., Lim L., and Manser E. Blot overlays with 32P-labeled fusion proteins. Methods (San Diego, Calif 24 (2001) 194-200
33. Ladbury J.E., Lemmon M.A., Zhou M., Green J., Botfield M.C., and Schlessinger J. Measurement of the binding of tyrosyl phosphopeptides to SH2 domains: a reappraisal. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 3199-3203
34. Pluk H., Dorey K., and Superti-Furga G. Autoinhibition of c-Abl. Cell 108 (2002) 247-259
35. Machida K., Thompson C.M., Dierck K., Jablonowski K., Karkkainen S., Liu B., Zhang H., Nash P.D., Newman D.K., Nollau P., Pawson T., Renkema G.H., Saksela K., Schiller M.R., Shin D.G., and Mayer B.J. High-throughput phosphotyrosine profiling using SH2 domains. Mol. Cell 26 (2007) 899-915
36. Goss V.L., Lee K.A., Moritz A., Nardone J., Spek E.J., MacNeill J., Rush J., Comb M.J., and Polakiewicz R.D. A common phosphotyrosine signature for the Bcr-Abl kinase. Blood 107 (2006) 4888-4897
37. Cowan-Jacob S.W., Fendrich G., Manley P.W., Jahnke W., Fabbro D., Liebetanz J., and Meyer T. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure (Camb) 13 (2005) 861-871
38. Juang J.L., and Hoffmann F.M. Drosophila abelson interacting protein (dAbi) is a positive regulator of abelson tyrosine kinase activity. Oncogene 18 (1999) 5138-5147
39. Ikeguchi A., Yang H.Y., Gao G., and Goff S.P. Inhibition of v-Abl transformation in 3T3 cells overexpressing different forms of the Abelson interactor protein Abi-1. Oncogene 20 (2001) 4926-4934
40. Leng Y., Zhang J., Badour K., Arpaia E., Freeman S., Cheung P., Siu M., and Siminovitch K. Abelson-interactor-1 promotes WAVE2 membrane translocation and Abelson-mediated tyrosine phosphorylation required for WAVE2 activation. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 1098-1103
41. Goley E.D., and Welch M.D. The ARP2/3 complex: an actin nucleator comes of age. Nat. Rev., Mol. Cell Biol. 7 (2006) 713-726
42. Azam M., Latek R.R., and Daley G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112 (2003) 831-843